JP2025142197A5 - - Google Patents

Info

Publication number
JP2025142197A5
JP2025142197A5 JP2025078577A JP2025078577A JP2025142197A5 JP 2025142197 A5 JP2025142197 A5 JP 2025142197A5 JP 2025078577 A JP2025078577 A JP 2025078577A JP 2025078577 A JP2025078577 A JP 2025078577A JP 2025142197 A5 JP2025142197 A5 JP 2025142197A5
Authority
JP
Japan
Prior art keywords
following structure
compound
formula
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2025078577A
Other languages
English (en)
Japanese (ja)
Other versions
JP7808226B2 (ja
JP2025142197A (ja
Filing date
Publication date
Priority claimed from JP2022550119A external-priority patent/JP2023515101A/ja
Application filed filed Critical
Publication of JP2025142197A publication Critical patent/JP2025142197A/ja
Publication of JP2025142197A5 publication Critical patent/JP2025142197A5/ja
Priority to JP2026005770A priority Critical patent/JP2026067907A/ja
Application granted granted Critical
Publication of JP7808226B2 publication Critical patent/JP7808226B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2025078577A 2020-02-21 2025-05-09 神経変性疾患及びミトコンドリア病の治療用の組成物ならびにその使用方法 Active JP7808226B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026005770A JP2026067907A (ja) 2020-02-21 2026-01-16 神経変性疾患及びミトコンドリア病の治療用の組成物ならびにその使用方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062980143P 2020-02-21 2020-02-21
US62/980,143 2020-02-21
JP2022550119A JP2023515101A (ja) 2020-02-21 2021-02-22 神経変性疾患及びミトコンドリア病の治療用の組成物ならびにその使用方法
PCT/US2021/019113 WO2021168446A1 (en) 2020-02-21 2021-02-22 Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022550119A Division JP2023515101A (ja) 2020-02-21 2021-02-22 神経変性疾患及びミトコンドリア病の治療用の組成物ならびにその使用方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026005770A Division JP2026067907A (ja) 2020-02-21 2026-01-16 神経変性疾患及びミトコンドリア病の治療用の組成物ならびにその使用方法

Publications (3)

Publication Number Publication Date
JP2025142197A JP2025142197A (ja) 2025-09-30
JP2025142197A5 true JP2025142197A5 (enExample) 2025-10-07
JP7808226B2 JP7808226B2 (ja) 2026-01-28

Family

ID=77391353

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022550119A Withdrawn JP2023515101A (ja) 2020-02-21 2021-02-22 神経変性疾患及びミトコンドリア病の治療用の組成物ならびにその使用方法
JP2025078577A Active JP7808226B2 (ja) 2020-02-21 2025-05-09 神経変性疾患及びミトコンドリア病の治療用の組成物ならびにその使用方法
JP2026005770A Pending JP2026067907A (ja) 2020-02-21 2026-01-16 神経変性疾患及びミトコンドリア病の治療用の組成物ならびにその使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022550119A Withdrawn JP2023515101A (ja) 2020-02-21 2021-02-22 神経変性疾患及びミトコンドリア病の治療用の組成物ならびにその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026005770A Pending JP2026067907A (ja) 2020-02-21 2026-01-16 神経変性疾患及びミトコンドリア病の治療用の組成物ならびにその使用方法

Country Status (16)

Country Link
US (1) US20240018146A1 (enExample)
EP (1) EP4106874A4 (enExample)
JP (3) JP2023515101A (enExample)
KR (2) KR20220158290A (enExample)
CN (1) CN115515682B (enExample)
AU (1) AU2021222053A1 (enExample)
BR (1) BR112022016614A2 (enExample)
CA (1) CA3168531A1 (enExample)
CO (1) CO2022013603A2 (enExample)
CR (1) CR20220476A (enExample)
EC (1) ECSP22074210A (enExample)
IL (2) IL326926A (enExample)
MX (2) MX2022010309A (enExample)
PH (1) PH12022552518A1 (enExample)
WO (1) WO2021168446A1 (enExample)
ZA (1) ZA202210409B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3947390A4 (en) * 2019-04-03 2022-11-30 Mitokinin, Inc. COMPOSITIONS AND METHODS FOR THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE
CN119752781B (zh) * 2025-03-04 2025-07-01 中国农业大学 缓解成熟卵子老化的组合物、培养液、产品及方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9604361D0 (en) * 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
TW200508224A (en) * 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
HRP20120786T1 (hr) * 2006-02-02 2012-11-30 Millennium Pharmaceuticals, Inc. Inhibitori aktivirajuä†eg enzima e1
SG174772A1 (en) * 2006-09-11 2011-10-28 Curis Inc Multi-functional small molecules as anti-proliferative agents
EP2342178B1 (en) * 2008-09-02 2016-09-28 Sanofi Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof
AU2014214561C1 (en) * 2013-02-11 2019-01-17 Mitokinin, Inc. Compositions and methods for treating neurodegenerative diseases
WO2018237145A1 (en) * 2017-06-21 2018-12-27 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease

Similar Documents

Publication Publication Date Title
JP2021191784A5 (enExample)
JP2024516371A5 (enExample)
JP2024071370A5 (enExample)
JP2007522220A5 (enExample)
JP2021063088A5 (enExample)
JP2003531118A5 (enExample)
JP2021530451A5 (enExample)
JP2025094100A5 (enExample)
JP2006515626A5 (enExample)
JP2005523922A5 (enExample)
JP2022068329A5 (enExample)
JP2018521020A5 (enExample)
JP2010077141A5 (enExample)
JP2015508103A5 (enExample)
JP2017105793A5 (enExample)
JP2025111617A5 (enExample)
JP2015024998A5 (enExample)
JP2020532547A5 (enExample)
JP2018533593A5 (enExample)
JP2020507589A5 (enExample)
JP2002332234A5 (enExample)
JP2006523216A5 (enExample)
JP2010520214A5 (enExample)
JP2008513510A5 (enExample)
JPWO2024181437A5 (enExample)